Up a level |
RECOVERY Collaborative Group,
(2023)
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
The lancet. Diabetes & endocrinology, 11 (12).
S2213-8587(23)00253-X-S2213-8587(23)00253-X.
RECOVERY Collaborative Group,
(2024)
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.
The Lancet. Child & adolescent health, 8 (3).
S2352-4642(23)00316-4-S2352-4642(23)00316-4.